Monoclonal antibodies directed to CD20
US9616120B2 · kind B2 · utility
10Cited by
13References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 15, 2011 |
| Grant date | Apr 11, 2017 |
| Priority date | — |
| Expiry date | Feb 28, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.